| Revenue growth | ₹904cr in Q4 (-5% YoY); ₹2,461cr India revenue in FY26 (+9%). |
|---|---|
| Margins | Gross margin improved to 70%; adjusted EBITDA margin expanded 200bps to 27%. |
| Demand visibility | Branded business remains a double-digit growth driver; chronic growing at 19%. |
| Management confidence | High confidence in India branded business acceleration post-integration. |
Growth
Revenue ₹904cr (-5% YoY); adjusted EBITDA ₹241cr; adjusted PAT ₹150cr. Branded India business grew 11% in FY26.
Outlook
Merger with Torrent Pharma effective in 1-2 months. Guidance for gradual recovery to double-digit growth in India business.
Risks
Trade generics discontinuation impacting top-line; container constraints in West Asia and Asia; integration-led operational resets.
Earnings Call filed with BSE, NSE: JBCHEPHARM. Summary written with AI assistance from the document.
More from J B Chemicals & Pharmaceuticals Ltd
All →J B Chemicals & Pharmaceuticals Earnings Call: Key Takeaways
Q4 FY26 marked an operational reset following Torrent Pharma's acquisition of a controlling stake. Management focused on integration, distribution optimization, and rationalizing low-margin trade generics.
J B Chemicals & Pharmaceuticals Earnings Call: Key Takeaways
This was an operational reset quarter following Torrent Pharma's acquisition, marked by intentional portfolio pruning and alignment of trade practices with the new parent entity.
J B Chemicals & Pharmaceuticals Earnings Call: Key Takeaways
JB Pharma underwent an operational reset in Q4 FY26 following the Torrent Pharma acquisition. Revenue dipped 5% to ₹904cr due to the discontinuation of low-margin trade generics and distribution realignment.
JB Chemicals & Pharmaceuticals Q4 FY26 Results: Net Profit ₹101.4 Cr, Down 30.4% YoY
JB Chemicals & Pharmaceuticals Ltd reported revenue from operations of ₹904.2 Cr (-4.8% YoY) and net profit of ₹101.4 Cr (-30.4% YoY) for Q4 FY26.
- Key figure
- Net profit ₹101.4 Cr · -30.4% YoY